American Journal of Cardiovascular Drugs

Scope & Guideline

Advancing Knowledge in Heart Health

Introduction

Explore the comprehensive scope of American Journal of Cardiovascular Drugs through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore American Journal of Cardiovascular Drugs in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1175-3277
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2001 to 2024
AbbreviationAM J CARDIOVASC DRUG / Am. J. Cardiovasc. Drugs
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

The American Journal of Cardiovascular Drugs focuses on advancing knowledge and understanding in the field of cardiovascular pharmacotherapy. It serves as a platform for the dissemination of research findings, clinical studies, and reviews that address critical issues in cardiovascular medicine.
  1. Pharmacotherapy for Cardiovascular Diseases:
    The journal primarily emphasizes studies related to pharmacological treatments for various cardiovascular conditions, including heart failure, myocardial infarction, and arrhythmias.
  2. Meta-analyses and Systematic Reviews:
    A significant portion of the publications includes meta-analyses and systematic reviews that synthesize existing research to provide comprehensive insights into treatment efficacy and safety.
  3. Real-World Evidence:
    The journal publishes studies utilizing real-world data to assess the effectiveness and safety of cardiovascular drugs in everyday clinical practice, highlighting the practical implications of therapeutic choices.
  4. Emerging Therapies and Novel Agents:
    Research on new and emerging pharmacological agents for cardiovascular conditions is a key focus, showcasing advancements in drug development and innovative treatment strategies.
  5. Guideline-Directed Therapy:
    The journal emphasizes the importance of guideline-directed medical therapy, discussing strategies to optimize treatment adherence and improve patient outcomes.
The American Journal of Cardiovascular Drugs is currently witnessing several emerging themes and trends that reflect the evolving landscape of cardiovascular pharmacotherapy. These trends indicate a growing interest in innovative treatments and patient-centered care.
  1. SGLT2 Inhibitors and GLP-1 Receptor Agonists:
    There is a marked increase in studies focusing on the cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists, particularly in patients with heart failure and diabetes, showcasing their role in cardio-protection.
  2. Real-World Data Analyses:
    An emerging trend is the utilization of real-world data analyses to evaluate treatment outcomes, adherence, and healthcare resource utilization, providing insights that complement randomized controlled trials.
  3. Pharmacogenomics and Personalized Medicine:
    Research into pharmacogenomics and its application in personalized medicine is gaining traction, highlighting the importance of tailoring cardiovascular therapies to individual patient characteristics.
  4. Novel Antithrombotic Strategies:
    There is a rising interest in novel antithrombotic strategies and combination therapies, particularly in the context of high-risk patients and those with complex comorbidities.
  5. Health Economics and Cost-Effectiveness:
    Increasingly, studies evaluating the cost-effectiveness of cardiovascular therapies are appearing, reflecting a growing emphasis on the economic implications of treatment choices in healthcare.

Declining or Waning

While the journal maintains a robust focus on various aspects of cardiovascular pharmacotherapy, certain themes appear to be declining in prominence over recent years. These waning scopes reflect shifts in research interests and clinical priorities.
  1. Traditional Anticoagulation Strategies:
    Research focusing on traditional anticoagulants, such as warfarin, is becoming less frequent as newer direct oral anticoagulants (DOACs) gain prominence in clinical practice.
  2. Long-term Outcomes of Older Medications:
    Studies examining the long-term outcomes of older medications such as digoxin and certain beta-blockers are declining, as the focus shifts toward newer agents with better efficacy and safety profiles.
  3. Single-Agent Therapies:
    There is a noticeable decrease in publications centered around single-agent therapies, as combination therapies and multifactorial approaches gain attention for their enhanced effectiveness.

Similar Journals

VASCULAR PHARMACOLOGY

Connecting research and practice in vascular medicine.
Publisher: ELSEVIER SCIENCE INCISSN: 1537-1891Frequency: 12 issues/year

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology

Empowering cardiology through open access and collaboration.
Publisher: KARE PUBLISSN: 1016-5169Frequency: 8 issues/year

Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology is a prominent peer-reviewed journal dedicated to advancing the field of cardiology and cardiovascular medicine. Published by KARE PUBL, this journal has established itself as a key resource for researchers, healthcare professionals, and students since its inception in 1990. As an Open Access journal since 2017, it ensures that cutting-edge research and clinical findings are readily accessible to a global audience, thus fostering collaboration and knowledge sharing among the cardiology community. With its recent rank in the Q3 quartile for Cardiology and Cardiovascular Medicine in 2023, and a Scopus rank of #282 out of 387, the journal is positioned to enhance its influence in the cardiovascular field, offering valuable insights and promoting evidence-based practices. The journal covers a wide range of topics within cardiology and cardiovascular research, making it an essential platform for scholars aiming to contribute to the ongoing dialogue in this vital area of medicine. For those eager to stay updated with the latest research trends and clinical practices in cardiology, Turk Kardiyoloji Dernegi Arsivi represents a crucial resource.

World Journal of Cardiology

Shaping the landscape of cardiology for a healthier tomorrow.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1949-8462Frequency: 12 issues/year

World Journal of Cardiology, published by BAISHIDENG PUBLISHING GROUP INC, stands out as a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1949-8462, this journal serves a global audience, promoting knowledge dissemination and collaboration among researchers, healthcare professionals, and students dedicated to advancing cardiovascular health. The journal demonstrates its credibility and impact in the field by achieving a respectable Q2 ranking in the 2023 category of Cardiology and Cardiovascular Medicine. Notably, it is listed in the Scopus database, ranking #189 out of 387 journals, placing it in the 51st percentile, which underscores its relevance and contribution to contemporary cardiovascular research. Although it operates under a subscription model, the journal provides diverse access options, ensuring that critical findings reach a wide audience. Through its comprehensive scope and commitment to publishing high-quality articles, the World Journal of Cardiology plays a vital role in shaping the future of cardiovascular science, making it an invaluable asset for those involved in this essential discipline.

CIRCULATION RESEARCH

Elevating knowledge in the dynamic field of cardiovascular medicine.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0009-7330Frequency: 24 issues/year

CIRCULATION RESEARCH is a premier journal dedicated to advancing the field of cardiovascular science, focusing on innovative research in cardiology and physiology. Published by Lippincott Williams & Wilkins, this esteemed journal has been a cornerstone of cardiovascular research since its inception in 1953, maintaining rigorous standards of scholarly excellence. With an impressive impact factor and ranking in the top quartiles for both Cardiology and Cardiovascular Medicine (Q1) and Physiology (Q1), it holds a significant position in the Scopus database. This journal features cutting-edge studies aimed at understanding the mechanisms of cardiovascular health and disease, promoting the translation of research into clinical practice. Weekly issues provide practitioners and researchers alike with vital insights to keep abreast of the latest developments. Although it does not offer open access, CIRCULATION RESEARCH remains vital for professionals striving to enhance their knowledge and impact in the ever-evolving landscape of cardiovascular medicine.

Expert Review of Cardiovascular Therapy

Connecting Theory and Practice in Cardiovascular Therapy
Publisher: TAYLOR & FRANCIS INCISSN: 1477-9072Frequency: 12 issues/year

Expert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.

Revista de la Federacion Argentina de Cardiologia

Driving progress in cardiovascular research and practice.
Publisher: FEDERACION ARGENTINA CARDIOLOGIAISSN: 0326-646XFrequency: 4 issues/year

Revista de la Federacion Argentina de Cardiologia is a vital publication in the field of Cardiology and Cardiovascular Medicine, providing a platform for researchers and healthcare professionals to share significant findings and innovative concepts since its inception in 2012. Published by the Federacion Argentina Cardiology, this journal specifically addresses contemporary issues and advancements within cardiology, contributing to the scholarly dialogue essential for improving cardiovascular health. Despite being categorized in the Q4 quartile for 2023 and presently ranking #358 out of 387 in its field, the journal remains committed to fostering academic inquiry and disseminating valuable research for both local and global audiences. Although it is not an open-access journal, it strives to balance accessibility with rigorous academic standards, ensuring quality contributions that are critical for practitioners and students alike. The journal’s ongoing evaluation and adaptation in the ever-evolving landscape of cardiology underscore its importance in advancing cardiovascular science and practice.

CURRENT CARDIOLOGY REVIEWS

Empowering Practitioners with Cutting-Edge Research
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-403XFrequency: 4 issues/year

CURRENT CARDIOLOGY REVIEWS, an esteemed journal published by BENTHAM SCIENCE PUBL LTD, is a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1573-403X and E-ISSN of 1875-6557, this journal presents comprehensive reviews that contribute significantly to the advancement of scientific knowledge and clinical practices in cardiology. Operating with open access options, CURRENT CARDIOLOGY REVIEWS is dedicated to bridging the gap between research and practice, thereby encouraging interdisciplinary collaboration and knowledge sharing. The journal has been instrumental in disseminating high-impact findings, consistently maintaining a Q2 category ranking in both Cardiology and Cardiovascular Medicine, as well as within the miscellaneous categories of Medicine, highlighting its relevance and respect in the academic community. Researchers, practitioners, and students alike will find valuable insights into contemporary cardiovascular issues, practices, and innovations that promote better patient outcomes. Based in the United Arab Emirates, CURRENT CARDIOLOGY REVIEWS encourages global contributions and reflects the latest advancements up to the year 2024, solidifying its role as an essential publication for those engaged in the quest for excellence in cardiovascular health.

CARDIOVASCULAR DRUGS AND THERAPY

Championing breakthroughs in heart health solutions.
Publisher: SPRINGERISSN: 0920-3206Frequency: 6 issues/year

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

CIRCULATION JOURNAL

Advancing Cardiovascular Knowledge, One Study at a Time.
Publisher: JAPANESE CIRCULATION SOCISSN: 1346-9843Frequency: 12 issues/year

CIRCULATION JOURNAL, published by the Japanese Circulation Society, stands as a premier platform for cutting-edge research in the fields of Cardiology and Cardiovascular Medicine. With an impressive impact factor placing it in the Q1 quartile for both cardiology and general medicine, this journal is essential for researchers and practitioners seeking to stay at the forefront of cardiovascular science. The journal's accessible open access options ensure that groundbreaking studies are widely disseminated, reflecting its commitment to advancing medical knowledge and improving patient care. Since its inception in 1996, CIRCULATION JOURNAL has fostered a global dialogue on vital cardiovascular issues, making it a vital resource for academics, healthcare professionals, and students alike. With its base in Tokyo, Japan, the journal not only highlights regional advancements but also contributes significantly to the global medical community.

JACC-Basic to Translational Science

Connecting Basic Research to Clinical Excellence
Publisher: ELSEVIER SCIENCE INCISSN: 2452-302XFrequency: 12 issues/year

JACC-Basic to Translational Science, published by Elsevier Science Inc, is a distinguished open access journal that has been advancing the field of cardiology and cardiovascular medicine since its inception in 2016. With an ISSN of 2452-302X and an impressive Q1 ranking in Cardiology and Cardiovascular Medicine as per the 2023 category quartiles, the journal is recognized for its commitment to publishing high-quality research that bridges the gap between basic science and clinical application. Operating from its base in the United States, JACC-Basic to Translational Science is at the forefront of enriching the academic community and healthcare professionals with cutting-edge studies and insights. The journal's robust reach is highlighted by its rank of #14 out of 387 in Scopus for its pertinent subject area, placing it in the 96th percentile. It aims to provide an open access platform that fosters collaboration and the exchange of ideas to ensure the continuous advancement of cardiovascular research. Readers can easily access the latest findings and contribute to the ever-evolving landscape of cardiology through this esteemed publication.